Aloe barbadensis

Aloe barbadensis is a succulent plant whose latex fraction contains anthraquinone glycosides, primarily barbaloin (aloin A and B), which act as stimulant laxatives in the large intestine. These compounds are hydrolyzed by colonic bacteria into active aloe-emodin anthrones, increasing intestinal motility and fluid secretion to relieve constipation.

Origin & History

Aloe barbadensis Mill. (also known as Aloe vera or Barbados aloe) is a succulent plant native to arid regions of Africa and the Arabian Peninsula, now cultivated globally. The medicinal substance is the dried latex (succus siccatus) obtained from leaf exudate, concentrated and dried - distinct from the inner gel. It contains hydroxyanthracene derivatives (HADs), primarily anthrone-10-C-glycosides, standardized to not less than 28% HADs expressed as barbaloin.

Historical & Cultural Context

Used historically as a purgative/laxative in European traditional medicine for occasional constipation, with well-established use recognized by EMA/HMPC based on long market presence. Documented in pharmacopeias since at least 1962, with folk uses in WHO monographs including unverified claims for dermatitis, ulcers, tuberculosis, and fungal infections.

Health Benefits

• Short-term relief of occasional constipation - Traditional use recognized by EMA/HMPC based on pre-2006 marketing authorizations, though lacking recent clinical trials
• Stimulant laxative effect - Well-established use under Article 10a of Directive 2001/83/EC for bowel regulation
• Folk medicine applications for dermatitis and ulcers - No experimental or clinical support documented
• Traditional claims for blood sugar reduction - Unverified in clinical studies
• Historical use for fungal infections - No modern evidence supporting efficacy

How It Works

Barbaloin (aloin A and B) passes unabsorbed through the small intestine and is metabolized by colonic microbiota into aloe-emodin anthrones, the pharmacologically active metabolites. These anthrones inhibit Na+/K+-ATPase in colonocyte membranes, reducing sodium and water absorption while stimulating chloride secretion, increasing luminal fluid content. Simultaneously, aloe-emodin anthrones stimulate prostaglandin E2 synthesis and activate enteric neurons, accelerating peristaltic contractions in the large intestine.

Scientific Research

EMA/HMPC monographs note a lack of recent clinical trials supporting well-established use beyond traditional evidence. No key human RCTs, meta-analyses, or specific PubMed PMIDs for efficacy are detailed in the sources for short-term relief of occasional constipation. Pre-2006 data underpin well-established use based on marketing authorizations, but no specific study designs, sample sizes, or outcomes from modern trials are provided.

Clinical Summary

The European Medicines Agency (EMA) Committee on Herbal Medicinal Products (HMPC) granted Aloe barbadensis latex 'well-established use' status under Article 10a of Directive 2001/83/EC for short-term treatment of occasional constipation, based on documentation predating 2006 rather than recent randomized controlled trials. A limited number of older clinical studies with small sample sizes (typically under 100 participants) demonstrated onset of laxative effect within 6–12 hours of oral administration of standardized aloin doses of 20–30 mg. Quantified outcomes in these studies showed increased stool frequency and softer stool consistency, but high-quality double-blind RCTs with pre-registered protocols are absent from the modern literature. The evidence base is therefore classified as 'traditional use' in contemporary regulatory frameworks, meaning efficacy is plausible but not robustly confirmed by current clinical trial standards.

Nutritional Profile

Aloe barbadensis (Aloe vera) latex and gel contain distinct nutritional and bioactive profiles. Aloe latex (from pericyclic cells beneath the rind) is rich in anthraquinone glycosides, primarily aloin A and aloin B (barbaloin) at concentrations of 15–40% of dry weight, which are the primary laxative constituents. Aloe gel (inner leaf parenchyma) contains approximately 98.5–99.5% water; dry matter includes polysaccharides (acemannan, glucomannans) at 0.2–0.5% fresh weight, which contribute to viscosity and potential immunomodulatory effects. Protein content is low at approximately 0.1% fresh weight, comprising lectins and glycoproteins (e.g., aloctin A, B). Minerals present include calcium (~9.4 mg/100g), magnesium (~8.8 mg/100g), potassium (~150 mg/100g), sodium, zinc, and manganese at trace levels. Vitamins detected include vitamin C (~4.4 mg/100g fresh gel), vitamin E (alpha-tocopherol, ~0.04 mg/100g), B1, B2, B6, and choline at low concentrations. Bioactive compounds include anthraquinones (aloe-emodin, emodin, chrysophanol), chromones (aloesin, aloeresins), sterols (beta-sitosterol, campesterol, lupeol), and saponins. Bioavailability note: anthraquinone glycosides are poorly absorbed in the small intestine, reaching the colon where gut bacteria hydrolyze them to active aglycones (aloe-emodin) responsible for stimulant laxative action; acemannan has limited oral bioavailability and is partially degraded by intestinal microbiota before absorption.

Preparation & Dosage

For standardized dry extracts (folii succus siccatus): 5-15 mg hydroxyanthracene derivatives (HADs) daily, equivalent to 10-30 mg barbaloin, for short-term use not exceeding 1-2 weeks. Standardization requires not less than 28% HADs expressed as barbaloin per European Pharmacopoeia. No dosages specified for non-latex forms like gel or powder. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Psyllium husk, Senna, Cascara sagrada, Magnesium citrate, Probiotics

Safety & Interactions

Aloe barbadensis latex is contraindicated in individuals with intestinal obstruction, inflammatory bowel conditions (Crohn's disease, ulcerative colitis), appendicitis, abdominal pain of unknown origin, and severe dehydration with electrolyte imbalances. Chronic use or overuse can cause hypokalemia (low potassium), which may potentiate the effects of cardiac glycosides such as digoxin and interact with antiarrhythmic drugs; concurrent use with thiazide diuretics or corticosteroids further increases electrolyte depletion risk. Use is contraindicated during pregnancy due to potential stimulation of uterine contractions and is not recommended during breastfeeding, as anthraquinone metabolites may pass into breast milk. The EMA restricts recommended use to a maximum of 1–2 weeks without medical supervision, and long-term use is associated with melanosis coli (a benign but reversible pigmentation of the colon).